Patent US5445608A successfully refreshed from Google Patents.
Patent GB1444614A successfully refreshed from Google Patents.
US20050043752A1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and devices for maintaining patency of surgically created channels in a body organ
Assignee: Broncus Medical Inc
•
Filing: 2004-07-19
•
Granted: —
•
Expires: 2024-07-19
Abstract
Abstract This is directed to methods and devices suited for maintaining an opening in a wall of a body organ for an extended period. More particularly devices and methods are directed maintaining patency of channels that alter gaseous flow within a lung to improve the expiration cycle of, for instance, an individual having chronic obstructive pulmonary disease.
Inventors
- 👤 Loc Phan
- 👤 Ed Roschak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:17
CPC Classifications
A; A61; A61B; A61B17/00; A61B17/064; A61B17/08; A61B17/083; A61B17/10; A61B17/12; A61B17/12022; A61B17/12099; A61B17/12104; A61B17/00491; A61B17/00234; A61B2017/00238; A61B2017/00243; A61B2017/00247; A61B2017/00252; A61B2017/00743; A61B2017/00809; A61B18/00; A61B2018/00315; A61B2018/00541; A61F; A61F2/00; A61F2/02; A61F2/04; A61F2/06; A61F2002/068
Claims Analysis
Total Claims: 33
Claim 1
Independent Claim
85 words
1 . An implant for maintaining an artificial opening in a wall of a body organ, the implant comprising: a support member having a proximal portion, a mid portion, a distal portion, and an interior passage extending therethrough, where the proximal, and distal portions are all expandable and the proximal and distal portions are expandable to a greater size than the mid portion so that the support member forms a grommet shape; and a composition located on the support member and comprising an antiproliferative agent.
Claim 2
Dependent Claim
85 words
1 . An implant for maintaining an artificial opening in a wall of a body organ, the implant comprising: a support member having a proximal portion, a mid portion, a distal portion, and an interior passage extending therethrough, where the proximal, and distal portions are all expandable and the proximal and distal portions are expandable to a greater size than the mid portion so that the support member forms a grommet shape; and a composition located on the support member and comprising an antiproliferative agent.
Claim 3
Dependent Claim
15 words
2 . The implant of claim 1 , where the composition further comprises a polymer.
Claim 4
Dependent Claim
79 words
3 . The implant of claim 1 , where the composition comprises an amount of antiproliferative agent that does not exhibit substantial cytotoxicity but controls the healing response by suppressing hyperplasia of lung tissue, to maintain patency of an artificial opening located in the airway which allows for maintaining air passage between the opening and parenchyma for a sufficient time until the healing response of the lung tissue subsides such that the opening essentially becomes a natural airway passage.
Claim 5
Dependent Claim
38 words
4 . The implant of claim 2 , where the composition comprises both a release rate and an amount of antiproliferative substance sufficient to modify a healing response of the airway wall resulting from creation of the opening.
Claim 6
Dependent Claim
55 words
5 . The implant of claim 2 , where the polymer is selected from a group consisting of thermoplastic polymers, thermoset polymers, acrylate polymers, a blend of acrylate-methacrylate polymers, silicone elastomers, urethane elastomers, ethylene vinyl acetate polymers, polyethylene, polypropylene, PLA-PGA, PLA, PGA, polyortho-ester, polycapralactone, polyester, hydrogels, polystyrene, co-polymers of styrene-isobutylene-styrene, and combinations or blends thereof.
Claim 7
Dependent Claim
25 words
6 . The conduit of claim 2 , further comprising a dye located in the polymer to aid in identification of the implant during placement.
Claim 8
Dependent Claim
20 words
7 . The implant of claim 2 , where the composition fully covers an outer surface of the support member.
Claim 9
Dependent Claim
20 words
8 . The implant of claim 7 , where the polymer fully encapsulates an interior surface of the support member.
Claim 10
Dependent Claim
17 words
9 . The implant of claim 2 , where the support member comprises a second polymeric material.
Claim 11
Dependent Claim
17 words
10 . The implant of claim 9 , where the polymer and second polymeric material are bioabsorbable.
Claim 12
Dependent Claim
43 words
11 . The implant of claim 1 , where the support structure has at least one pocket where the antiproliferative substance is located in the pocket, and further comprising a polymer at least covering the pocket to act as a barrier to release.
Claim 13
Dependent Claim
16 words
12 . The implant of claim 1 , where the support member comprises a metallic material.
Claim 14
Dependent Claim
25 words
13 . The implant of claim 1 , where the support member comprises a plurality of members forming a mesh having a plurality of interstices.
Claim 15
Dependent Claim
22 words
14 . The implant of claim 13 , where the composition further comprises a polymer covering the members but not the interstices.
Claim 16
Dependent Claim
35 words
15 . The implant of claim 13 , the support member includes a plurality of folded control members that unfold upon expansion of the support member to limit an expanded diameter of the support member.
Claim 17
Dependent Claim
32 words
16 . The implant of claim 15 , where the folded control members form a shape selected from a group consisting of an s-shape, a v-shape, a u-shape, and a sinusoidal shape.
Claim 18
Dependent Claim
17 words
17 . The implant of claim 13 , where the antiproliferative substance comprises a microtubule stabilizing agent.
Claim 19
Dependent Claim
15 words
18 . The implant of claim 13 , where the microtubule stabilizing agent is paclitaxel.
Claim 20
Dependent Claim
17 words
19 . The implant of claim 1 , where the antiproliferative substance comprises a microtubule destabilizing agent.
Claim 21
Dependent Claim
33 words
20 . The implant of claim 19 , where the microtubule destabilizing agent is selected from the group comprising vincristine, vinblastine, podophylotoxin, estramustine, noscapine, griseofulvin, dicoumarol, a vinca alkaloid, and a combination thereof.
Claim 22
Dependent Claim
30 words
21 . The implant of claim 1 , where the antiproliferative substance comprises a substance selected from the group consisting of steroids, non-steroidal anti-inflammatories, and d-actinomycin, and a combination thereof.
Claim 23
Dependent Claim
16 words
22 . The implant of claim 1 , where the antiproliferative substance comprises a cytostatic agent.
Claim 24
Dependent Claim
28 words
23 . The implant of claim 22 , where the cytostatic agent is selected from the group consisting of: sirolimus, everolimus, ABT-578, biolimus, tacrolimus, and a combination thereof.
Claim 25
Dependent Claim
14 words
24 . The implant of claim 1 , further comprising a mucus affecting substance.
Claim 26
Dependent Claim
26 words
25 . The implant of claim 24 , where the mucus affecting substance is selected from a group consisting of mucolytics, rhDnase, and a combination thereof.
Claim 27
Dependent Claim
23 words
26 . The implant of claim 1 , further comprising at least one visualization mark disposed on a portion of the support member.
Claim 28
Dependent Claim
25 words
27 . The implant of claim 26 , where the visualization mark comprises a stripe circumferentially disposed about at least a portion the support member.
Claim 29
Dependent Claim
20 words
28 . The implant of claim 1 , further comprising a one-way valve in fluid communication with the interior passage.
Claim 30
Dependent Claim
20 words
29 . The implant of claim 1 , further comprising an antibiotic substance carried on or within the support member.
Claim 31
Dependent Claim
17 words
30 . The implant of claim 1 , further comprising a barrier located within the support member.
Claim 32
Dependent Claim
14 words
31 . The implant of claim 1 , further comprising a fibrin reducing substance.
Claim 33
Dependent Claim
26 words
32 . The implant of claim 31 , where the fibrin reducing substance is selected from a group consisting of streptokinase, urokinase, and tissue plasminogen activator.
References Cited (Backward Citations)
US2127903A
Cited
US3174851A
Cited
US3433226A
Cited
US3351463A
Cited
US3617060A
Cited
US3556079A
Cited
US3565062A
Cited
US3753700A
Cited
US3707151A
Cited
US3779234A
Cited
US3823717A
Cited
US3874388A
Cited
US3889688A
Cited
US5263992A
Cited
US5509900A
Cited
US5366504A
Cited
US5562922A
Cited
US5855598A
Cited
US6099563A
Cited
US5674242A
Cited
US6719781B1
Cited
US6299604B1
Cited
US6335029B1
Cited
US6342591B1
Cited
US20050177144A1
Cited
US6458153B1
Cited
US6379382B1
Cited
US6941950B2
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.